Primary Prevention (Aspirin) — EECC MCQ

Correct answer: B — No routine aspirin; focus on risk factor control

Explanation lettering: B = shown as A · C = shown as B · E = shown as C · A = shown as D · D = shown as E

USPSTF advises against routine aspirin in adults >=60 for primary prevention due to bleeding risk exceeding benefit; emphasize BP, lipids, lifestyle. A/B/D/E: Antiplatelet therapy is not recommended for primary prevention in this age group. The keyed option is the best answer only in the stated clinical context. The alternatives would require different findings, contraindications, thresholds or treatment circumstances that are not present. Apply the recommendation alongside comorbidity, interactions, patient preference and the current local pathway. Review response and safety-net for deterioration, treatment failure or adverse effects; reconsider the diagnosis if the expected response does not occur. Apply this conclusion only to the clinical circumstances stated, with appropriate specialist review, contraindication checks, shared decision-making and follow-up. Reassess if the physiology, treatment response or competing risk changes. The competing options would require a different haemodynamic profile, diagnosis, procedural indication or risk balance from the one described here.

Reference: USPSTF (2022): Aspirin Use to Prevent CVD (Primary Prevention): https://bnf.nice.org.uk/